Figure 4

Heterogeneity of response between different lesions in the same patient. (A–E) The responses of different lesions within the same patient were compared. Waterfall plots showing the percentage change in lesion size (black) and the percentage change in nE (red) between the baseline and first on-treatment scan for five patients. Lesions are assigned identification numbers from 1 to 4 or 1 to 7, as appropriate, and are classified according to response subgroup 1, 2, 3 or 4 as appropriate. (A) A 69-year-old man treated with sunitinib: lesions 1–3 are lung metastases and lesion 4 is a mediastinal lymph node metastasis. (B) A 57-year-old man treated with sunitinib: lesions 1,3 and 4 are liver metastases and lesion 2 is a hilar lymph node metastasis. (C) An 82-year-old man treated with pazopanib: lesion 1 is a hilar lymph node metastasis, lesions 2 and 3 are head of pancreas metastases and lesion 4 is a tail of pancreas metastasis. (D) A 69-year-old woman treated with sunitinib: lesions 1–4 are all lung metastases. (E) A 52-year-old woman treated with sunitinib: lesions 1–6 are lesions present in either the pleura or lung, whereas lesion 7 is a liver metastasis. (F and G) Pseudo-coloured arterial phase contrast-enhanced CT images of two lesions from the patient featured in panel E are shown. The baseline and first on-treatment scans of lesion 1, a pleural metastasis (F), and of lesion 7, a liver metastasis (G), are shown.